Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

导出 OA

翻译打印收藏纠错

第一作者： Spyros,Chalkias

第一单位： Moderna, Inc., Cambridge, MA, USA. spyros.chalkias@modernatx.com.

作者： Spyros,Chalkias ^[1] ; Charles,Harper ^[2] ; Keith,Vrbicky ^[2] ; Stephen R,Walsh ^[3] ; Brandon,Essink ^[4] ; Adam,Brosz ^[5] ; Nichole,McGhee ^[6] ; Joanne E,Tomassini ^[6] ; Xing,Chen ^[6] ; Ying Chang ^[6] ; Andrea,Sutherland ^[6] ; David C,Montefiori ^[7] ; Bethany,Girard ^[6] ; Darin K,Edwards ^[6] ; Jing Feng ^[6] ; Honghong,Zhou ^[6] ; Lindsey R,Baden ^[3] ; Jacqueline M,Miller ^[6] ; Rituparna,Das ^[6]

作者单位： Moderna, Inc., Cambridge, MA, USA. spyros.chalkias@modernatx.com. ^[1] Meridian Clinical Research, Norfolk, NE, USA. ^[2] Brigham and Women's Hospital, Boston, MA, USA. ^[3] Meridian Clinical Research, Omaha, NE, USA. ^[4] Meridian Clinical Research, Grand Island, NE, USA. ^[5] Moderna, Inc., Cambridge, MA, USA. ^[6] Department of Surgery and Duke Human Vaccine Institute, Durham, NC, USA. ^[7]

主题词成年人(Adult);人类(Humans);抗体, 中和(Antibodies, Neutralizing);疫苗, 联合(Vaccines, Combined);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic);临床试验, Ⅲ期(主题)(Clinical Trials, Phase III as Topic)

DOI 10.1038/s41467-023-38892-w

PMID 37612300

发布时间 2023-11-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交